Top Page
Quanterix
(NASDAQ:QTRX)
Quanterix (QTRX) vs. SPDR S&P 500 ETF (SPY)
Quanterix Business Overview & Revenue Model
Quanterix Earnings Call Summary
Quanterix Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 135.44M | 122.37M | 104.95M | 110.56M | 86.38M |
| Gross Profit | 81.12M | 70.65M | 46.24M | 61.73M | 48.18M |
| EBITDA | -44.26M | -38.09M | -65.73M | -53.24M | -27.27M |
| Net Income | -38.53M | -32.33M | -96.70M | -57.69M | -31.53M |
Balance Sheet | |||||
| Total Assets | 406.53M | 425.01M | 434.20M | 501.53M | 271.05M |
| Cash, Cash Equivalents and Short-Term Investments | 289.12M | 321.32M | 338.74M | 396.46M | 181.58M |
| Total Debt | 37.37M | 41.46M | 44.10M | 21.89M | 30.80M |
| Total Liabilities | 76.50M | 78.08M | 75.26M | 60.58M | 64.92M |
| Stockholders Equity | 330.04M | 346.93M | 358.94M | 440.95M | 206.13M |
Cash Flow | |||||
| Free Cash Flow | -38.53M | -22.69M | -60.00M | -61.52M | -27.30M |
| Operating Cash Flow | -35.16M | -18.90M | -48.27M | -47.91M | -23.36M |
| Investing Cash Flow | -82.27M | -148.40M | -11.21M | -6.34M | -626.00K |
| Financing Cash Flow | 456.00K | 2.69M | 2.31M | 270.80M | 96.24M |
Quanterix Technical Analysis
Quanterix Risk Analysis
Quanterix Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $156.32M | 23.36 | 16.56% | ― | 14.85% | 64.96% | |
59 Neutral | $259.98M | ― | -36.14% | ― | 13.06% | 41.50% | |
55 Neutral | $158.08M | ― | -407.50% | ― | 32.24% | -66.93% | |
52 Neutral | $133.45M | ― | -60.68% | ― | 19.84% | 5.77% | |
50 Neutral | $257.07M | ― | -14.51% | ― | 7.71% | -38.97% | |
47 Neutral | $164.93M | ― | -20.42% | ― | -18.80% | 26.16% | |
46 Neutral | C$201.68M | -3.28 | -23.14% | 1.87% | 20.75% | -0.36% |
Quanterix Corporate Events
On July 18, 2025, Quanterix Corporation announced a plan to reduce operating costs and preserve cash through a series of terminations as part of its integration strategy following the acquisition of Akoya Biosciences, Inc. This move is expected to result in annualized cash savings of approximately $18 million, primarily through headcount reductions to be completed by the third quarter of 2025. However, the company anticipates incurring expenses of around $2.5 million for severance. The actual financial impact may vary based on several assumptions, and Quanterix has acknowledged potential risks and uncertainties that could affect the expected outcomes.
The most recent analyst rating on (QTRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
On July 14, 2025, Quanterix Corporation announced a plan to terminate certain executives of its newly acquired subsidiary, Akoya Biosciences, Inc., as part of an integration strategy to achieve cost savings and operational efficiencies. The move is expected to result in annual cash savings of approximately $2.8 million, although it will incur expenses of around $3.3 million in 2025 for severance payments. The company acknowledges that actual results may vary from these estimates and additional charges could arise.
The most recent analyst rating on (QTRX) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
On July 8, 2025, Quanterix Corporation completed its acquisition of Akoya Biosciences, creating a comprehensive platform for measuring biomarkers across blood and tissue. This acquisition is expected to expand Quanterix’s market from $1 billion to $5 billion and accelerate its path to profitability by 2026. As part of the merger, Akoya designated Scott Mendel and Myla Lai-Goldman, MD, to join Quanterix’s Board of Directors, replacing Martin D. Madaus, PhD, and Sarah Hlavinka, who resigned on July 7, 2025. The merger positions Quanterix as a scaled leader in early disease detection for neurology, oncology, and immunology markets.
The most recent analyst rating on (QTRX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
On June 26, 2025, Quanterix Corporation’s board announced that the 2025 Annual Meeting of Stockholders will be held virtually on September 23, 2025. Due to the meeting’s date being more than 30 days from the previous year’s meeting, deadlines for stockholder proposals and nominations have been revised, with new deadlines set for July 11 and July 25, 2025, to comply with SEC rules and the company’s bylaws.
The most recent analyst rating on (QTRX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
On May 7, 2025, Quanterix‘s Board of Directors approved a cost-reduction plan to save $15 million in 2025, with annualized savings of $30 million. This includes a significant reduction in workforce, expected to be completed by the end of the second quarter of 2025. Additionally, Quanterix announced a strategic move to integrate its Simoa® ONE assay kits with over 20,000 flow cytometers globally, enhancing its market reach and reducing the need for new equipment purchases. The company also reported a net loss for the first quarter of 2025 but is implementing measures to achieve positive cash flow by 2026, including a merger with Akoya Biosciences, expected to close in June 2025.
The most recent analyst rating on (QTRX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
On April 28, 2025, Quanterix Corporation announced an amended merger agreement with Akoya Biosciences, revising the terms of their previously announced merger. Under the new terms, Quanterix will issue fewer shares and pay $20 million in cash to Akoya shareholders, with Quanterix shareholders owning 84% of the combined entity. This strategic move aims to create value for shareholders and leverage combined resources to drive synergies and expedite profitability. The merger is expected to close in the second quarter of 2025, pending Akoya shareholder approval and other customary conditions.